COSTA MESA, CA / ACCESSWIRE / July 18, 2024 / SIPP Industries (OTC PINK:SIPC), a multifaceted corporation specializing in the manufacturing and distribution of commercial and consumer products within the cannabis industry, is excited to announce its ambitious quarterly plans and projections, featuring significant advancements from its partner, Calypso Pharmaceuticals.

Calypso Pharmaceuticals and SIPP Industries have been working diligently on AVEINA Melanoma topical, a groundbreaking formulation utilizing 1000mg of Nano Emulsified CBD and Peptide P16 to actively reduce cellular growth for all Melanoma cells. The company is also researching other beneficial peptides, such as Peptide P10 and Melanotan II, to further reduce Melanoma cell growth. These developments are crucial steps in providing quality analytics and data, proving that the targeted absorption of Nano Emulsified CBD combined with beneficial peptides will bring relief and results to affected areas in Melanoma cases.

In collaboration with hemp production companies in the United States, Australia, and Brazil, Calypso Pharmaceuticals and SIPP Industries are creating innovative cGMP product formulations for consumers. Utilizing nanotechnology, these unique formulations ensure high bioavailability and precise particle sizes for various delivery routes, including oral and topical formats such as tinctures, muscle/pain topicals, pet products and wellness beverages. These targeted abilities position Calypso Pharmaceuticals and SIPP Industries at the forefront of cannabinoid innovation.

Looking ahead, Calypso Pharmaceuticals and SIPP Industries have been discussing options to expand its footprint with established brands in the United States into four additional markets by Spring 2025. With base operations in Oklahoma City and headquarters in Dallas Texas, this expansion will strengthen Calypso Pharmaceuticals and SIPP Industries' presence across the cannabis community.

"Through strategic advancements and pivotal partnerships, SIPP Industries is pioneering new frontiers in cannabinoid innovation, poised to lead with revolutionary treatments for Melanoma and beyond," said Adam Graziano, CEO of SIPP Industries.

"We are thrilled with the progress we are making in our research and development efforts. Our focus on combining nano emulsified cannabinoids with innovative peptides is paving the way for revolutionary treatments for Melanoma and other diseases.

By expanding our operations and forming strategic partnerships, we are poised to lead the industry in cannabinoid innovation," said Jakob Jorgensen, CEO of Calypso Pharmaceuticals.

In addition, SIPP Industries is actively engaging with multiple candidates for the CFO role to establish a robust executive team. Concurrently, the company is relocating its headquarters to Dallas, Texas. These strategic moves are aimed at enhancing its ability to navigate the dynamic landscapes of the cannabis and pharmaceutical industries, especially with the expanding partnership with Calypso Pharmaceuticals.

About SIPP Industries

SIPP Industries is a multifaceted corporation specializing in the manufacturing and distribution of commercial and consumer products within the cannabis industry.

Website: http://www.sippindustries.com

Facebook: https://www.facebook.com/SippIndustries

Twitter: @SippIndustries

About Calypso Pharmaceuticals

Calypso Pharmaceuticals, based in Dallas, Texas, is on a mission to establish a leading global brand with the most comprehensive portfolio of innovative cannabis-based therapeutics. The company is dedicated to creating products that ensure a healthy and comfortable life, formulating a wide range of medications for chronic conditions such as Alzheimer's, anxiety, chronic pain, depression, melanoma, obesity, and more. Calypso Pharmaceuticals aims to provide a calm and satisfactory experience in administering and utilizing cannabis-based medicine.

Website: https://calypsopharmaceuticals.com

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended and section 21e of the Securities and Exchange Act of 1934, as amended. Those statements include the intent, belief or current expectations of the Company and its management team. Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations. Some or all of the events or results anticipated by these forward-looking statements may not occur. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Accomplishing the strategy described herein is significantly dependent upon numerous factors, many that are not in management's control.

Contact:

Sipp Industries, Inc.
Investor Relations
ir@sippindustries.com

SOURCE: Sipp Industries, Inc.